CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia...
Phase 1
Durham, North Carolina, United States and 3 other locations
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Durham, North Carolina, United States and 51 other locations
in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia...
Phase 2
Durham, North Carolina, United States and 8 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Chapel Hill, North Carolina, United States and 10 other locations
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Durham, North Carolina, United States and 47 other locations
Adult T-cell leukemia/lymphoma (ATLL) is a rare form of cancer found mostly among people from the Caribbean islands, Western Africa, Brazil,...
Phase 2
Chapel Hill, North Carolina, United States and 3 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Chapel Hill, North Carolina, United States and 23 other locations
in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...
Phase 1, Phase 2
Durham, North Carolina, United States and 33 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Chapel Hill, North Carolina, United States of America and 110 other locations
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...
Phase 2
Durham, North Carolina, United States and 85 other locations
Clinical trials
Research sites
Resources
Legal